Clinical Trial Update: Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

SPEDOX-6, a single protein encapsulated doxorubicin, is being studied in Phase 1/2 trials for several advanced cancers and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Kras-mutant Tumors
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Soft Tissue Sarcoma
• Triple-negative Breast Cancer

Drugs mentioned

• SPEDOX-6 (single protein encapsulated doxorubicin)

Snippet

Sponsor: University of California, Irvine | Conditions: Soft-tissue Sarcoma, Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING